Veeva Systems Inc. $VEEV Shares Sold by First Trust Advisors LP

First Trust Advisors LP cut its holdings in Veeva Systems Inc. (NYSE:VEEV) by 9.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 647,320 shares of the technology company’s stock after selling 71,524 shares during the period. First Trust Advisors LP owned about 0.40% of Veeva Systems worth $186,415,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the business. EverSource Wealth Advisors LLC increased its holdings in shares of Veeva Systems by 199.7% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,224 shares of the technology company’s stock valued at $640,000 after acquiring an additional 1,482 shares during the last quarter. Invesco Ltd. boosted its holdings in Veeva Systems by 60.4% in the second quarter. Invesco Ltd. now owns 286,374 shares of the technology company’s stock valued at $82,470,000 after purchasing an additional 107,847 shares in the last quarter. CW Advisors LLC purchased a new position in Veeva Systems in the second quarter valued at approximately $611,000. PharVision Advisers LLC increased its stake in Veeva Systems by 103.7% in the second quarter. PharVision Advisers LLC now owns 1,805 shares of the technology company’s stock valued at $520,000 after purchasing an additional 919 shares during the last quarter. Finally, Groupe la Francaise raised its holdings in Veeva Systems by 128.1% during the second quarter. Groupe la Francaise now owns 1,398 shares of the technology company’s stock worth $401,000 after purchasing an additional 785 shares in the last quarter. 88.20% of the stock is owned by hedge funds and other institutional investors.

Veeva Systems Stock Performance

Shares of VEEV opened at $242.24 on Friday. Veeva Systems Inc. has a fifty-two week low of $201.54 and a fifty-two week high of $310.50. The firm has a 50-day simple moving average of $281.00 and a 200-day simple moving average of $278.57. The company has a market capitalization of $39.82 billion, a price-to-earnings ratio of 47.13, a price-to-earnings-growth ratio of 1.79 and a beta of 1.05.

Veeva Systems (NYSE:VEEV) last issued its quarterly earnings results on Thursday, November 20th. The technology company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.95 by $0.09. Veeva Systems had a return on equity of 13.68% and a net margin of 27.93%.The firm had revenue of $0.81 million for the quarter, compared to analysts’ expectations of $792.37 million. During the same quarter in the previous year, the firm posted $1.75 EPS. The firm’s revenue for the quarter was up 16.0% on a year-over-year basis. Veeva Systems has set its FY 2026 guidance at 7.930-7.93 EPS and its Q4 2026 guidance at 1.920-1.920 EPS. Equities research analysts forecast that Veeva Systems Inc. will post 4.35 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently commented on VEEV shares. Evercore ISI increased their target price on shares of Veeva Systems from $285.00 to $295.00 and gave the company an “in-line” rating in a research report on Thursday, August 28th. Jefferies Financial Group restated a “buy” rating and issued a $330.00 price objective on shares of Veeva Systems in a research note on Monday, November 24th. Oppenheimer reaffirmed an “outperform” rating and set a $325.00 price objective on shares of Veeva Systems in a report on Thursday, August 28th. BMO Capital Markets initiated coverage on Veeva Systems in a report on Thursday, November 13th. They issued a “market perform” rating and a $300.00 target price for the company. Finally, Piper Sandler upped their target price on Veeva Systems from $325.00 to $355.00 and gave the company an “overweight” rating in a research report on Thursday, August 28th. Twenty investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $305.88.

Insider Transactions at Veeva Systems

In other Veeva Systems news, SVP Jonathan Faddis sold 720 shares of the company’s stock in a transaction on Monday, October 6th. The shares were sold at an average price of $298.12, for a total transaction of $214,646.40. Following the completion of the transaction, the senior vice president owned 7,868 shares in the company, valued at approximately $2,345,608.16. This represents a 8.38% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Eleni Nitsa Zuppas sold 6,000 shares of the firm’s stock in a transaction on Tuesday, October 7th. The stock was sold at an average price of $306.62, for a total transaction of $1,839,720.00. Following the completion of the sale, the insider owned 25,325 shares of the company’s stock, valued at $7,765,151.50. This trade represents a 19.15% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 24,665 shares of company stock worth $7,438,000 over the last 90 days. 10.30% of the stock is currently owned by insiders.

Veeva Systems Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.